AMLX

Amylyx Pharmaceuticals Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth 1/10
  • Value 5/10
Amylyx Pharmaceuticals sales and earnings growth
AMLX Growth
Low
  • Revenue Y/Y 100.00%
  • EPS Y/Y 52.26%
  • FCF Y/Y 41.80%
Amylyx Pharmaceuticals gross and profit margin trends
AMLX Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y -100.00%
Amylyx Pharmaceuticals net debt vs free cash flow
AMLX Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage NA

Amylyx Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks